Amelia Deitchman, PharmD, PhD

Assistant Professor
Department of Clinical Pharmacy
Deitchman
[email protected]
Phone: +1 415 476-1148

Private practice

1001 Potrero Ave
Bldg 100 Rm 157
San Francisco

Links

UCSF Profiles

Affiliations

Education programs

PharmD Degree Program

UCSF centers, institutes, and research programs

Drug Research Unit (DRU)

What I do

My research seeks to inform novel therapeutic strategies to cure HIV through better understanding of pharmacokinetics and pharmacodynamics of individual and combinations of candidate drugs. Based out of the UCSF Drug Research Unit (DRU), I work with a multidisciplinary team of clinicians-scientists and researchers here at UCSF and across collaborative international networks on design, execution, and analysis of cure-focused clinical trials in people living with HIV. Our ultimate goal is to identify curative strategies to cure the nearly 37 million people with HIV.

Since the beginning of the COVID-19 pandemic, I’ve applied my expertise to evaluating treatments for COVID-19 and its long term sequelae, primarily through the UCSF-based Long-term Impact of Infection With Novel Coronavirus (LIINC) cohort and recently as a member of the NIH RECOVER Interventions Task Force.

Departmental research area

clinical research

My research expertise

infectious disease, pharmacokinetics/pharmacodynamics, HIV cure clinical pharmacology, pharmacometric modelling and simulation, clinical translational PK/PD, COVID-19 pharmacology

Professional background

Degrees

PhD, Pharmaceutical Sciences, minor in Applied Statistics, University of Florida, 2017
PharmD, University of Florida, 2013

Postgraduate training

T32 Fellowship, Clinical Pharmacology, University of California, San Francisco, 2020

Research keywords

  • computational modeling
  • pharmacokinetics
  • Pharmacometrics
  • Protein Binding
  • HIV
  • infectious disease
  • tuberculosis
  • PK/PD
  • clinical pharmacology
  • precision medicine
  • Anti-Bacterial Agents
  • drug design
  • Critical Illness
  • pharmacokinetics
  • Anti-Infective Agents
  • Palivizumab
  • Respiratory Syncytial Virus Infections
  • Chelating Agents
  • Pharmaceutical Preparations
  • HIV-1
  • Microdialysis
  • HIV Seropositivity
  • Minocycline
  • HIV Infections

Publications

Buck AM, Deitchman AN, Takahashi S, Lu S, Goldberg SA, Bodansky A, Kung A, Hoh R, Williams MC, Kerbleski M, Maison DP, Deveau TM, Munter SE, Lombardo J, Wrin T, Petropoulos CJ, Durstenfeld MS, Hsue PY, Kelly JD, Greenhouse B, Martin JN, Deeks SG, Peluso MJ, Henrich TJ. The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms. J Med Virol. 2023 11; 95(11):e29216.
Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN. A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models. Res Sq. 2023 Oct 23.
Ernest JP, Goh JJN, Strydom N, Wang Q, van Wijk RC, Zhang N, Deitchman A, Nuermberger E, Savic RM. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. Eur Respir J. 2023 08; 62(2).
Buck AM, Deveau TM, Henrich TJ, Deitchman AN. Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies. Viruses. 2023 05 09; 15(5).
Buck AM, Deitchman AN, Takahashi S, Lu S, Goldberg SA, Hoh R, Williams MC, Kerbleski M, Deveau TM, Munter SE, Lombardo J, Wrin T, Petropoulos CJ, Durstenfeld MS, Hsue PY, Kelly JD, Greenhouse B, Martin JN, Deeks SG, Peluso MJ, Henrich TJ. The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms. medRxiv. 2023 Mar 31.
Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, Baizer L, Goldman JD, Rouphael N, Deitchman A, Fine J, Fontelo P, Kim AY, Shaw G, Stratford J, Ceger P, Costantine MM, Fisher L, O'Brien L, Maughan C, Quigley JG, Gabbay V, Mohandas S, Williams D, McComsey GA. Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023; 14:1129459.
Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, Chan F, Lu S, Goldberg SA, Hoh R, Tai V, Torres L, Iyer NS, Deswal M, Ngo LH, Buitrago M, Rodriguez A, Chen JY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Deitchman AN, Hellmuth J, Spinelli MA, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Deeks SG, Hunt PW, Henrich TJ. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023 02 01; 133(3).
Ernest JP, Ni Goh JJ, Strydom N, Wang Q, van Wijk RC, Zhang N, Deitchman A, Nuermberger E, Savic RM. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. bioRxiv. 2023 Jan 20.
Rahman F, Brates I, Aweeka F, Bosch RJ, Deitchman A, Nixon D, Aberg JA. Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV-1 with suppressed HIV-1 RNA and LDL cholesterol <130 mg/dL. HIV Med. 2023 06; 24(6):749-753.
George AF, McGregor M, Gingrich D, Neidleman J, Marquez RS, Young KC, Thanigaivelan KL, Greene WC, Tien PC, Deitchman AN, Spitzer TL, Roan NR. Female Genital Fibroblasts Diminish the In Vitro Efficacy of PrEP against HIV. Viruses. 2022 08 04; 14(8).
Beckford-Vera DR, Flavell RR, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C, Fehrman E, Pardons M, Kumar S, Deitchman AN, Ravanfar V, Schulte B, Wu IK, Pan T, Reeves JD, Nixon CC, Iyer NS, Torres L, Munter SE, Hyunh T, Petropoulos CJ, Hoh R, Franc BL, Gama L, Koup RA, Mascola JR, Chomont N, Deeks SG, VanBrocklin HF, Henrich TJ. First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nat Commun. 2022 03 09; 13(1):1219.
Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman EA, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021 08 10; 36(6):109518.
Peluso MJ, Munter SE, Lynch KL, Yun C, Torres L, Iyer NS, Donatelli J, Ryan L, Deitchman AN, Deeks SG, Rutishauser RL, Henrich TJ. Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. Open Forum Infect Dis. 2021 Aug; 8(8):ofab393.
Bigelow KM, Deitchman AN, Li SY, Barnes-Boyle K, Tyagi S, Soni H, Dooley KE, Savic RM, Nuermberger EL. Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis. J Infect Dis. 2021 06 04; 223(11):1855-1864.
Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, Hecht FM, Martin JN, Deeks SG, Aweeka FT, Hunt PW. Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. J Infect Dis. 2021 05 20; 223(9):1621-1630.
Peluso MJ, Deitchman AN, Torres L, Iyer NS, Nixon CC, Munter SE, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman E, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19. medRxiv. 2021 Mar 01.
Gingrich D, Deitchman AN, Kantor A, Huang L, Stein JH, Currier JS, Hsue PY, Ribaudo HJ, Aweeka FT, ACTG 5314 Protocol Team. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):651-658.
Neely M, Onufrak N, Scheetz MH, Avedissian S, Lakota E, Deitchman AN, Gonzalez D. Supporting Precision Dosing in Drug Labeling. Clin Pharmacol Ther. 2021 01; 109(1):37-41.
Henrich TJ, Schreiner C, Cameron C, Hogan LE, Richardson B, Rutishauser RL, Deitchman AN, Chu S, Rogers R, Thanh C, Gibson EA, Zarinsefat A, Bakkour S, Aweeka F, Busch MP, Liegler T, Baker C, Milush J, Deeks SG, Stock PG. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. Am J Transplant. 2021 05; 21(5):1765-1779.
Deitchman AN. The Risk of Treating Populations Instead of Patients. CPT Pharmacometrics Syst Pharmacol. 2019 05; 8(5):256-258.
Deitchman AN, Singh RSP, Derendorf H. Nonlinear Protein Binding: Not What You Think. J Pharm Sci. 2018 07; 107(7):1754-1760.
McDonough CW, Magvanjav O, Sá ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, Johnson JA. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.
Deitchman AN, Singh RSP, Rand KH, Derendorf H. Enhanced in vitro activity of tigecycline in the presence of chelating agents. Int J Antimicrob Agents. 2018 May; 51(5):799-802.
Singh RSP, Mukker JK, Drescher SK, Deitchman AN, Derendorf H. A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding. Int J Antimicrob Agents. 2017 Apr; 49(4):449-455.
Deitchman AN, Heinrichs MT, Khaowroongrueng V, Jadhav SB, Derendorf H. Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization. AAPS J. 2017 03; 19(2):334-342.
Deitchman A, de Jong D, Barbour A, Derendorf H. Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections. Expert Rev Anti Infect Ther. 2016; 14(11):997-1006.
Singh RSP, Mukker JK, Deitchman AN, Drescher SK, Derendorf H. Role of Divalent Metal Ions in Atypical Nonlinear Plasma Protein Binding Behavior of Tigecycline. J Pharm Sci. 2016 11; 105(11):3409-3414.
Deitchman AN, Derendorf H. Measuring drug distribution in the critically ill patient. Adv Drug Deliv Rev. 2014 Nov 20; 77:22-6.
B?dingen FV, Gonzalez D, Tucker AN, Derendorf H. Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis. 2014 Feb 01; 2(1):17-42.